Understanding how a genetic variant affects white blood cell counts in certain populations
Official title: Evaluating the clinical implications for ACKR1/DARC associated neutropenia
Funded at University of California, San Francisco · NIH-11091664 · Data updated 2026-11-12
This study is looking at how a certain gene variation affects white blood cell counts in African Americans, with the goal of helping doctors better diagnose infections and manage chemotherapy for patients with this genetic difference.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | August 15, 2023 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $619,254 |
| NIH project number | 5R01HL170627-03 |
| Project ID | NIH-11091664 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include African American individuals and others with African ancestry who may carry the DARC/ACKR1 genetic variant.
✕Less likely to help
Patients who do not have the DARC/ACKR1 genetic variant or those from populations not affected by this genetic difference may not benefit from this research.
What this research studies
This research investigates the impact of a specific genetic variant associated with the Duffy Antigen Receptor Chemokine (DARC/ACKR1) on white blood cell and neutrophil counts, particularly in African American populations. By analyzing how this genetic difference influences blood cell counts, the study aims to improve the accuracy of diagnosing infections and managing chemotherapy in patients with this variant. The research will involve collecting and analyzing blood samples to better understand the clinical implications of these findings.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnoses and tailored treatments for patients with the DARC/ACKR1 genetic variant, improving their overall healthcare outcomes.
How similar studies have gone: Previous research has identified the genetic variant's effects, but this study aims to translate those findings into clinical practice, making it a novel approach.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Ziv, Elad — University of California, San Francisco
- Study coordinator: Ziv, Elad
Related research
Other NIH-funded projects on the same topics.
-
Severe Chronic Neutropenia Registry for Patients
A patient-facing registry that tracks severe chronic low neutrophil counts to improve understanding and care for people with this condition.
-
Severe Chronic Neutropenia Registry to Improve Care
A patient-focused registry gathers information from adults with severe chronic neutropenia to better understand infections, treatments, and outcomes over time.
-
Severe Chronic Neutropenia Registry: Finding Better Ways to Prevent Infections
A patient-focused registry at a leading hospital helps people with severe chronic neutropenia learn how the condition progresses and how treatments work over time.
-
Stimulant that grows donor stem cells in the body to speed neutropenia recovery after chemotherapy and stem cell transplant
A drug given during or right before stem cell transplant helps donor stem cells multiply quickly inside the patient to shorten neutropenia after treatment.
-
Stimulant to grow stem cells in the body to speed recovery after chemotherapy and stem cell transplant
A new drug given briefly before transplant aims to help patients recover their blood and immune system faster after chemotherapy or stem cell transplant.
-
PointCheck: a home-based, non-invasive neutropenia monitor for chemotherapy patients
A portable, non-invasive device helps cancer patients on chemotherapy monitor neutropenia from home so doctors can prevent serious infections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.